Metropolis Healthcare Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Acute volume surprise hits Q3: A sharp, unexpected drop in acute-illness patient volumes dragged overall growth, even as chronic testing held up and revenue growth stayed in line with peers.
• B2C strength offsets B2B drag: B2C revenue grew 15% and now makes up 55% of the mix, while institutional business and seeding-market B2B underperformance pulled down the blended number.
• Core Diagnostics acquisition closes soon: The deal is expected to finalize by end-February, will be EPS-accretive from year 1, but will dilute margins for 12 months before converging to company levels in 2–3 years.
• Micro-market pricing delivers a net 2% lift: Customized price corrections (up in strong markets, down in others) are expected to add a couple of percentage points to revenue starting Q4.
• What to watch next quarter: Whether the Q4 volume rebound materializes as early indicators suggest, the pace of Core Diagnostics integration, and any bolt-on B2C acquisition announcements in North India.

Q3 Performance: The Acute Volume Surprise

• Acute illness volumes fell unexpectedly: Chronic disease testing performed well in Q3, but acute-illness volumes were materially lower, surprising management given that revenue growth was similar to peers. Ground-level data and pharma industry indicators confirmed the acute-illness weakness was a seasonal fluctuation, not a competitive shift.
• Patient volume growth decelerated YTD: Year-to-date patient volume growth slipped to 6% from 7–8% the prior year, partly because of the deliberate defocus on high-volume, low-margin institutional business. Management expects a recovery to the 7–8% range by year-end.
• Institutional business dragged the blended growth rate: B2C grew 15% and B2B grew 11%, which would have yielded ~13% combined, but institutional revenue (not a strategic priority) and the loss of some government contracts pulled the overall number lower.
• Seeding markets underperformed: Newer labs in seeding markets lack a large B2C presence, and B2B discounting pressure and competition hurt performance there. Focus markets (five key cities) did quite well.

Surendran Chemmenkotil: "While revenue growth for Metropolis in Q3 has been similar to peers, we are surprised by the low volume of acute patients. When we try to understand if this is a competitive or seasonal issue, our understanding from the ground and data points of the pharma industry reflects that in Q3, chronic diseases did quite well, but acute illnesses were lower."

B2C Strategy and Channel Mix

• B2C now 55% of revenue, up from 53%: Growth was driven by robust clinician engagement and the company-owned center model, which delivers a higher NPS (86%) and higher revenue per patient than franchisee-led peers. The fixed-cost burden is higher in the short run but creates operating leverage as centers mature.
• B2C share target is 8–10% higher over 2–3 years: Management expects the B2C segment to gain further share from the current 55%, which will help improve gross margins over time even though specialized tests carry slightly lower gross margins than routine tests.
• TruHealth realization gap is narrow: B2C realization on TruHealth packages is only 3–4% higher than B2B, not the 15–20% an analyst had assumed. Most TruHealth revenue already comes from B2C channels (digital plus brick-and-mortar).
• Recommendation engine rolled out in Q3: When a patient walks into a center, the system now suggests additional tests as the next best action in their healthcare journey, an initiative expected to increase tests per patient and revenue per patient.
• Price and volume are not tightly linked in healthcare: Management pushed back on the idea that lowering prices reliably drives higher volumes, arguing that a stronger brand enables better pricing and profitability regardless.

Ameera Shah: "See, we are assuming that price and volume have a direct linkage. Actually, in health care, we find that, that linkage is not as obvious. So just because you lower price doesn't mean that you're able to pick up larger volumes."

Micro-Market Strategy and Pricing

• Four-pronged approach tailored to each geography: The strategy covers (1) market-relevant price corrections (up or down), (2) a revamped partner model with greater autonomy, (3) logistics improvements for better turnaround time, and (4) tailored test menus per market. A INR 5,000 wellness package works in Mumbai but not in small UP towns, so prices were adjusted down in some markets and taken up in Mumbai, Pune, and Maharashtra where Metropolis has stronger presence.
• Net pricing impact is approximately +2%: Across all markets, the combined effect of upward and downward adjustments is expected to add a couple of percentage points to overall revenue starting Q4.
• B2B discounting held steady: Some competitors continued efforts to reduce discounts on the tail end of the B2B segment, but Metropolis has not increased discounting to B2B clients in the last 2–3 quarters.

Surendran Chemmenkotil: "So we just looked at all the operators in that market, and we adjusted the prices accordingly. And some of the markets, let's say, Mumbai or Pune or parts of Maharashtra, where we have much bigger strength, we have an opportunity to take the prices up, right? So we have taken the prices up in the market."

Network Expansion and Margin Trajectory

• Lab expansion phase ends in Q4: Metropolis added 7 new labs and 125 centers this quarter, bringing its presence to over 750 towns. The final lap of lab expansion in Q4 will conclude the FY25–26 lab build-out, after which focus shifts to accelerated collection-center additions and gradual EBITDA and margin accretion.
• New lab margin ramp-up follows a predictable curve: Year 1 of a new lab generates negative single-digit EBITDA; by the end of year 2 it reaches double-digit positive EBITDA; and within 2.5–3 years it normalizes to company-level margins.
• Organic margin opportunity exists as expansion slows: With lab expansion winding down, year 2 will see much less drag from new labs, and operational leverage should improve. Cost growth (~10.8% currently) should trend relatively lower as center expansion (less capex-heavy than labs) improves productivity.
• Mumbai density target: The company aims to have a Metropolis collection center every 2–2.5 km in Mumbai, adding 30–50 centers per year, a trajectory expected to continue for the next couple of years.

Core Diagnostics Acquisition and Inorganic Pipeline

• Core Diagnostics closes effective March 1: A steering committee is in place for integration, focusing on restructuring while retaining key talent, driving synergies, and integrating IT systems. The acquisition reinforces leadership in high-end specialty diagnostics including genomics, molecular diagnostics, and oncology.
• Margin dilution is temporary, EPS accretion is immediate: Core's margin profile will be lower than Metropolis for the first 12 months and will dilute group margins temporarily. Margins are expected to move up fairly in year 1 and reach Metropolis levels within 2–3 years. The deal is EPS-accretive from year 1.
• Bolt-on B2C acquisitions in North India are in advanced discussions: Targets are city-leading B2C businesses with high EBITDA, high ROCE, and strong operating cash flow to EBITDA ratios. They are purchased at lower EBITDA multiples than public companies trade at, with the promoter pathologist typically retaining a minority stake and continuing to operate the business.
• Inorganic growth is strategic, not a revenue accelerator: Organic growth remains the mainstay; acquisitions serve as entry points into new testing capabilities or geographies, providing a base to then catapult from.

Ameera Shah: "While we anticipate Core revenue growth to be strong and margins of Core to move up fairly in year 1 of acquisition, the margin profile will be lower than Metropolis for the first 12 months and will dilute the margin temporarily. It will take up to 2 to 3 years to reach the margin-Metropolis margin profile."

Competitive Landscape and Industry Structure

• Online players took share from the unorganized sector, not incumbents: The pace of online market-share gains peaked during COVID and has not sustained; online players now grow at the same pace as the rest of the industry and still do not make a profit. No new players have entered since 2022, and hospital chains and pharma chains that entered have their own challenges.
• Consolidation runway remains long: The top five chains account for less than 5–7% of the industry, and the unorganized space is roughly 85%. There is no saturation in the industry.
• Metropolis is outpacing peers in core markets: The company continues to be the fastest-growing player in Bombay and Maharashtra, including versus peers who have made acquisitions there.

Ameera Shah: "I think we have to remember that the online players actually took market share not really from the large incumbents like us, they actually took it from the unorganized sector... And really, the market has gone back to where the online players are growing actually at the same pace now as the rest of the industry and not significantly faster. And obviously, they still continue to not make any profit on it."

Guidance & Commitments

Key Metrics